Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, S. Y.
Right arrow Articles by Press, O. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, S. Y.
Right arrow Articles by Press, O. W.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 16, 3270-3278, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Follow-up of relapsed B-cell lymphoma patients treated with iodine-131- labeled anti-CD20 antibody and autologous stem-cell rescue

SY Liu, JF Eary, SH Petersdorf, PJ Martin, DG Maloney, FR Appelbaum, DC Matthews, SA Bush, LD Durack, DR Fisher, TA Gooley, ID Bernstein and OW Press
Department of Medicine, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, USA.

PURPOSE: Radioimmunotherapy (RIT) is a promising treatment approach for B-cell lymphomas. This is our first opportunity to report long-term follow-up data and late toxicities in 29 patients treated with myeloablative doses of iodine-131-anti-CD20 antibody (anti-B1) and autologous stem-cell rescue. PATIENTS AND METHODS: Trace-labeled biodistribution studies first determined the ability to deliver higher absorbed radiation doses to tumor sites than to lung, liver, or kidney at varying amounts of anti-B1 protein (0.35, 1.7, or 7 mg/kg). Twenty- nine patients received therapeutic infusions of single-agent (131)I- anti-B1, given at the protein dose found optimal in the biodistribution study, labeled with amounts of (131)I (280 to 785 mCi [10.4 to 29.0 GBq]) calculated to deliver specific absorbed radiation doses to the normal organs, followed by autologous stem-cell support. RESULTS: Major responses occurred in 25 patients (86%), with 23 complete responses (CRs; 79%). The nonhematopoietic dose-limiting toxicity was reversible cardiopulmonary insufficiency, which occurred in two patients at RIT doses that delivered > or = 27 Gy to the lungs. With a median follow-up time of 42 months, the estimated overall and progression-free survival rates are 68% and 42%, respectively. Currently, 14 of 29 patients remain in unmaintained remissions that range from 27+ to 87+ months after RIT. Late toxicities have been uncommon except for elevated thyroid-stimulating hormone (TSH) levels found in approximately 60% of the subjects. Two patients developed second malignancies, but none have developed myelodysplasia (MDS). CONCLUSION: Myeloablative (131)I-anti- B1 RIT is relatively well tolerated when given with autologous stem- cell support and often results in prolonged remission durations with few late toxicities.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
J. N. Winter, D. J. Inwards, S. Spies, G. Wiseman, D. Patton, W. Erwin, A. W. Rademaker, B. B. Weitner, S. F. Williams, M. S. Tallman, et al.
Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
J. Clin. Oncol., April 1, 2009; 27(10): 1653 - 1659.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. M. Illidge, M. Bayne, N. S. Brown, S. Chilton, M. S. Cragg, M. J. Glennie, Y. Du, V. Lewington, J. Smart, J. Thom, et al.
Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy
Blood, February 12, 2009; 113(7): 1412 - 1421.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. G. Rajendran, A. K. Gopal, D. R. Fisher, L. D. Durack, T. A. Gooley, and O. W. Press
Myeloablative 131I-Tositumomab Radioimmunotherapy in Treating Non-Hodgkin's Lymphoma: Comparison of Dosimetry Based on Whole-Body Retention and Dose to Critical Organ Receiving the Highest Dose
J. Nucl. Med., May 1, 2008; 49(5): 837 - 844.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. J. Green, J. M. Pagel, A. Pantelias, N. Hedin, Y. Lin, D. S. Wilbur, A. Gopal, D. K. Hamlin, and O. W. Press
Pretargeted Radioimmunotherapy for B-Cell Lymphomas
Clin. Cancer Res., September 15, 2007; 13(18): 5598s - 5603s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. K. Gopal, J. G. Rajendran, T. A. Gooley, J. M. Pagel, D. R. Fisher, S. H. Petersdorf, D. G. Maloney, J. F. Eary, F. R. Appelbaum, and O. W. Press
High-Dose [131I]Tositumomab (anti-CD20) Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults >= 60 Years Old With Relapsed or Refractory B-Cell Lymphoma
J. Clin. Oncol., April 10, 2007; 25(11): 1396 - 1402.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. Song, Y. Du, G. Sgouros, A. Prideaux, E. Frey, and R. L. Wahl
Therapeutic Potential of 90Y- and 131I-Labeled Anti-CD20 Monoclonal Antibody in Treating Non-Hodgkin's Lymphoma with Pulmonary Involvement: A Monte Carlo-Based Dosimetric Analysis
J. Nucl. Med., January 1, 2007; 48(1): 150 - 157.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. M. Reilly
Radioimmunotherapy of Solid Tumors: The Promise of Pretargeting Strategies Using Bispecific Antibodies and Radiolabeled Haptens
J. Nucl. Med., February 1, 2006; 47(2): 196 - 199.
[Full Text] [PDF]

Home page
 BloodHome page
J. N. Winter
Will radioimmunotherapy replace TBI?
Blood, October 15, 2005; 106(8): 2601 - 2602.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. M. Richman, S. J. DeNardo, R. T. O'Donnell, A. Yuan, S. Shen, D. S. Goldstein, J. M. Tuscano, T. Wun, H. K. Chew, P. N. Lara, et al.
High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody
Clin. Cancer Res., August 15, 2005; 11(16): 5920 - 5927.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Vose, P. J. Bierman, C. Enke, J. Hankins, G. Bociek, J. C. Lynch, and J. O. Armitage
Phase I Trial of Iodine-131 Tositumomab With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Relapsed Non-Hodgkin's Lymphoma
J. Clin. Oncol., January 20, 2005; 23(3): 461 - 467.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Forero, P. L. Weiden, J. M. Vose, S. J. Knox, A. F. LoBuglio, J. Hankins, M. L. Goris, V. J. Picozzi, D. B. Axworthy, H. B. Breitz, et al.
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
Blood, July 1, 2004; 104(1): 227 - 236.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. G. Rajendran, D. R. Fisher, A. K. Gopal, L. D. Durack, O. W. Press, and J. F. Eary
High-Dose 131I-Tositumomab (Anti-CD20) Radioimmunotherapy for Non-Hodgkin's Lymphoma: Adjusting Radiation Absorbed Dose to Actual Organ Volumes
J. Nucl. Med., June 1, 2004; 45(6): 1059 - 1064.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Z. Yao, M. Zhang, K. Garmestani, D. B. Axworthy, R. W. Mallett, A. R. Fritzberg, L. J. Theodore, P. S. Plascjak, W. C. Eckelman, T. A. Waldmann, et al.
Pretargeted {alpha} Emitting Radioimmunotherapy Using 213Bi 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-Tetraacetic Acid-Biotin
Clin. Cancer Res., May 1, 2004; 10(9): 3137 - 3146.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
J. Uchida, Y. Lee, M. Hasegawa, Y. Liang, A. Bradney, J. A. Oliver, K. Bowen, D. A. Steeber, K. M. Haas, J. C. Poe, et al.
Mouse CD20 expression and function
Int. Immunol., January 1, 2004; 16(1): 119 - 129.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. K. Gopal, T. A. Gooley, D. G. Maloney, S. H. Petersdorf, J. F. Eary, J. G. Rajendran, S. A. Bush, L. D. Durack, J. Golden, P. J. Martin, et al.
High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis
Blood, October 1, 2003; 102(7): 2351 - 2357.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. H. Brouwers, W. C. A. M. Buijs, E. Oosterwijk, O. C. Boerman, C. Mala, P. H. M. De Mulder, F. H. M. Corstens, P. F. A. Mulders, and W. J. G. Oyen
Targeting of Metastatic Renal Cell Carcinoma with the Chimeric Monoclonal Antibody G250 Labeled with 131I or 111In: An Intrapatient Comparison
Clin. Cancer Res., September 1, 2003; 9(10): 3953S - 3960.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Hosing, R. M. Saliba, P. McLaughlin, B. Andersson, M. A. Rodriguez, L. Fayad, F. Cabanillas, R. E. Champlin, and I. F. Khouri
Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma
Ann. Onc., May 1, 2003; 14(5): 737 - 744.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. M. Pagel, N. Hedin, K. Subbiah, D. Meyer, R. Mallet, D. Axworthy, L. J. Theodore, D. S. Wilbur, D. C. Matthews, and O. W. Press
Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas
Blood, March 15, 2003; 101(6): 2340 - 2348.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. J. Buchsbaum and A. F. LoBuglio
Targeting of 125I-Labeled B Lymphocyte Stimulator
J. Nucl. Med., March 1, 2003; 44(3): 434 - 436.
[Full Text] [PDF]

Home page
 BloodHome page
B. D. Cheson
Radioimmunotherapy of non-Hodgkin lymphomas
Blood, January 15, 2003; 101(2): 391 - 398.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. E. Juweid
Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma: From Clinical Trials to Clinical Practice
J. Nucl. Med., November 1, 2002; 43(11): 1507 - 1529.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. R. Colnot, G. J. Ossenkoppele, J. C. Roos, J. J. Quak, R. de Bree, P. K. Borjesson, P. C. Huijgens, G. B. Snow, and G. A. M. S. van Dongen
Reinfusion of Unprocessed, Granulocyte Colony-stimulating Factor-stimulated Whole Blood Allows Dose Escalation of 186Relabeled Chimeric Monoclonal Antibody U36 Radioimmunotherapy in a Phase I Dose Escalation Study
Clin. Cancer Res., November 1, 2002; 8(11): 3401 - 3406.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. O. Dillman
Radiolabeled Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoma
J. Clin. Oncol., August 15, 2002; 20(16): 3545 - 3557.
[Full Text] [PDF]

Home page
 BloodHome page
M. Ladetto, P. Corradini, S. Vallet, F. Benedetti, U. Vitolo, M. Martelli, M. Brugiatelli, P. Coser, A. Perrotti, I. Majolino, et al.
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)
Blood, August 13, 2002; 100(5): 1559 - 1565.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. G. Jurcic, S. M. Larson, G. Sgouros, M. R. McDevitt, R. D. Finn, C. R. Divgi, A. M. Ballangrud, K. A. Hamacher, D. Ma, J. L. Humm, et al.
Targeted alpha particle immunotherapy for myeloid leukemia
Blood, July 30, 2002; 100(4): 1233 - 1239.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. McLaughlin
Progress and Promise in the Treatment of Indolent Lymphomas
Oncologist, June 1, 2002; 7(3): 217 - 225.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. E. Witzig, L. I. Gordon, F. Cabanillas, M. S. Czuczman, C. Emmanouilides, R. Joyce, B. L. Pohlman, N. L. Bartlett, G. A. Wiseman, N. Padre, et al.
Randomized Controlled Trial of Yttrium-90-Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma
J. Clin. Oncol., May 15, 2002; 20(10): 2453 - 2463.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. M. Goldenberg
Targeted Therapy of Cancer with Radiolabeled Antibodies
J. Nucl. Med., May 1, 2002; 43(5): 693 - 713.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. K. Gopal, J. G. Rajendran, S. H. Petersdorf, D. G. Maloney, J. F. Eary, B. L. Wood, T. A. Gooley, S. A. Bush, L. D. Durack, P. J. Martin, et al.
High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma
Blood, May 1, 2002; 99(9): 3158 - 3162.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. M. Vose, B. C.-H. Chiu, B. D. Cheson, J. Dancey, and J. Wright
Update on Epidemiology and Therapeutics for Non-Hodgkin's Lymphoma
Hematology, January 1, 2002; 2002(1): 241 - 262.
[Abstract] [Full Text]

Home page
 Protein Eng Des SelHome page
A. M. Wu, G. J. Tan, M. A. Sherman, P. Clarke, T. Olafsen, S. J. Forman, and A. A. Raubitschek
Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange
Protein Eng. Des. Sel., December 1, 2001; 14(12): 1025 - 1033.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
O. W. Press, M. Corcoran, K. Subbiah, D. K. Hamlin, D. S. Wilbur, T. Johnson, L. Theodore, E. Yau, R. Mallett, D. L. Meyer, et al.
A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts
Blood, October 15, 2001; 98(8): 2535 - 2543.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. D. Cheson
Some Like It Hot!
J. Clin. Oncol., October 1, 2001; 19(19): 3908 - 3911.
[Full Text]

Home page
 BloodHome page
S. J. Horning, R. S. Negrin, R. T. Hoppe, S. A. Rosenberg, N. J. Chao, G. D. Long, B. W. Brown, and K. G. Blume
High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial
Blood, January 15, 2001; 97(2): 404 - 409.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. L. Korn, S. G. Arbuck, J. M. Pluda, R. Simon, R. S. Kaplan, and M. C. Christian
Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?
J. Clin. Oncol., January 1, 2001; 19(1): 265 - 272.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
O. W. Press, J. P. Leonard, B. Coiffier, R. Levy, and J. Timmerman
Immunotherapy of Non-Hodgkin's Lymphomas
Hematology, January 1, 2001; 2001(1): 221 - 240.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Colombat, G. Salles, N. Brousse, P. Eftekhari, P. Soubeyran, V. Delwail, E. Deconinck, C. Haioun, C. Foussard, C. Sebban, et al.
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation
Blood, January 1, 2001; 97(1): 101 - 106.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Schultz, Y. Lin, J. Sanderson, Y. Zuo, D. Stone, R. Mallett, S. Wilbert, and D. Axworthy
A Tetravalent Single-chain Antibody-Streptavidin Fusion Protein for Pretargeted Lymphoma Therapy
Cancer Res., December 1, 2000; 60(23): 6663 - 6669.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
S. Mathas, A. Rickers, K. Bommert, B. Dörken, and M. Y. Mapara
Anti-CD20- and B-cell Receptor-mediated Apoptosis: Evidence for Shared Intracellular Signaling Pathways
Cancer Res., December 1, 2000; 60(24): 7170 - 7176.
[Abstract] [Full Text]

Home page
 JNMHome page
D. R. Colnot, J. J. Quak, J. C. Roos, A. van Lingen, A. J. Wilhelm, G. J. van Kamp, P. C. Huijgens, G. B. Snow, and G. A.M.S. van Dongen
Phase I Therapy Study of 186Re-Labeled Chimeric Monoclonal Antibody U36 in Patients with Squamous Cell Carcinoma of the Head and Neck
J. Nucl. Med., December 1, 2000; 41(12): 1999 - 2010.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
O. W. Press, J. F. Eary, T. Gooley, A. K. Gopal, S. Liu, J. G. Rajendran, D. G. Maloney, S. Petersdorf, S. A. Bush, L. D. Durack, et al.
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas
Blood, November 1, 2000; 96(9): 2934 - 2942.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. S. Kaminski, J. Estes, K. R. Zasadny, I. R. Francis, C. W. Ross, M. Tuck, D. Regan, S. Fisher, J. Gutierrez, S. Kroll, et al.
Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience
Blood, August 15, 2000; 96(4): 1259 - 1266.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Xu, S. A. Leadon, Y. Yu, C. M. Boyer, K. O’Briant, K. Ward, A. McWatters, X. Zhao, D. S. Bae, K. DeSombre, et al.
Synergistic Interaction between Anti-p185HER-2 Ricin A Chain Immunotoxins and Radionuclide Conjugates for Inhibiting Growth of Ovarian and Breast Cancer Cells That Overexpress HER-2
Clin. Cancer Res., August 1, 2000; 6(8): 3334 - 3341.
[Abstract] [Full Text]

Home page
 ANN INTERN MEDHome page
O. W. Press
Emerging Immunotherapies for Non-Hodgkin Lymphomas: The Tortoise Approaches the Finish Line
Ann Intern Med, June 6, 2000; 132(11): 916 - 918.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B.-R. Wei, M.-A. Ghetie, and E. S. Vitetta
The Combined Use of an Immunotoxin and a Radioimmunoconjugate to Treat Disseminated Human B-Cell Lymphoma in Immunodeficient Mice
Clin. Cancer Res., February 1, 2000; 6(2): 631 - 642.
[Abstract] [Full Text]

Home page
 JCOHome page
A. Josting, M. Reiser, U. Rueffer, B. Salzberger, V. Diehl, and A. Engert
Treatment of Primary Progressive Hodgkin’s and Aggressive Non-Hodgkin’s Lymphoma: Is There a Chance for Cure?
J. Clin. Oncol., January 14, 2000; 18(2): 332 - 332.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. E. Witzig, C. A. White, G. A. Wiseman, L. I. Gordon, C. Emmanouilides, A. Raubitschek, N. Janakiraman, J. Gutheil, R. J. Schilder, S. Spies, et al.
Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+ B-Cell Non-Hodgkin's Lymphoma
J. Clin. Oncol., December 1, 1999; 17(12): 3793 - 3803.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. S. Freedman, D. Neuberg, P. Mauch, R. J. Soiffer, K. C. Anderson, D. C. Fisher, R. Schlossman, E. P. Alyea, T. Takvorian, H. Jallow, et al.
Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma
Blood, November 15, 1999; 94(10): 3325 - 3333.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Levy
Karnofsky Lecture: Immunotherapy of Lymphoma
J. Clin. Oncol., November 1, 1999; 17(90001): 7 - 12.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
O. C. Boerman, M. H. G. C. Kranenborg, E. Oosterwijk, G. L. Griffiths, W. J. McBride, W. J. G. Oyen, M. de Weijert, J. Oosterwijk-Wakka, H. J. Hansen, and F. H. M. Corstens
Pretargeting of Renal Cell Carcinoma: Improved Tumor Targeting with a Bivalent Chelate
Cancer Res., September 1, 1999; 59(17): 4400 - 4405.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Pavlinkova, B. J. M. Booth, S. K. Batra, and D. Colcher
Radioimmunotherapy of Human Colon Cancer Xenografts Using a Dimeric Single-Chain Fv Antibody Construct
Clin. Cancer Res., September 1, 1999; 5(9): 2613 - 2619.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1998 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online